Evidence map›Paper›PMID 39601398›Full record

ArticleKorean circulation journal2025

Increasing Very Low-Dose Edoxaban Prescription: Effectiveness and Safety Data of Korean AF Patients.

JungMin Choi, So-Young Yang, So-Ryoung Lee, Min Soo Cho, Kyung-Yeon Lee, Hyo-Jeong Ahn, Soonil Kwon, Myung-Jin Cha, Jun Kim, Gi-Byoung Nam and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Korean circulation journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

JungMin Choi *Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-4633-640X
So-Young Yang *Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-5973-7889
So-Ryoung LeeDivision of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-6351-5015
Min Soo ChoDivision of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. d070294@gmail.com.ORCID https://orcid.org/0000-0001-9867-4991
Kyung-Yeon LeeDivision of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-6458-6130
Hyo-Jeong AhnDivision of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-3590-0378
Soonil KwonDivision of Cardiology, Department of Internal Medicine, Seoul Boramae Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0002-4791-6855
Myung-Jin ChaDivision of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-6180-0157
Jun KimDivision of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-3573-638X
Gi-Byoung NamDivision of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-4391-5406
Kee-Joon ChoiDivision of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-9055-049X
Eue-Keun ChoiDivision of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-0411-6372
Seil OhDivision of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-2504-9615
Gregory Y H LipDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7566-1626

Funding

Korea Medical Device Development Fund 1711138358Korea Medical Device Development Fund HI20C1662Korea Medical Device Development Fund KMDF_PR_20200901_0173Korean Cardiac Research Foundation 202103-01Ministry of Health and Welfare HC21C0028NIEHS NIH HHS 27302C0028
6 · The paper itself

Abstract

BACKGROUND AND

objectivesEvidence remains limited on the real-world prescription of very low-dose oral anticoagulation among frail patients with atrial fibrillation (AF). We described the practice patterns, effectiveness, and safety of very low-dose edoxaban (15 mg once daily).

methodsPatients with AF prescribed edoxaban 15 mg once daily in 2 tertiary hospitals between 2016 and September 2022 were included. Baseline clinical characteristics and clinical outcomes of interest were thromboembolic and bleeding events.

resultsA total of 674 patients were included (mean age 78.3±9.1, 49.7% aged ≥80 years, 49.3% women, median follow-up 1.0±1.2 years). Mean CHA

conclusionsThe prescription of very low-dose edoxaban was increased over time, attributable to various clinical factors. The use of very low-dose edoxaban reduced the expected risk of thromboembolic events.

Indexed as

Atrial fibrillationBleedingFactor Xa inhibitorOff-label useStroke

Identifiers

PMID39601398
PMCPMC11922598

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.